newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

BIAFBIAFW
  • bioAffinity Technologies, Inc. announced a 1-for-15 reverse stock split of its common stock effective August 24, 2026.
  • The stock will begin trading on the Nasdaq Capital Market under the symbol BIAF on a post-split basis.
  • The reverse split was approved by stockholders at the annual meeting held on April 30, 2026.
  • Every 15 shares of common stock will be exchanged for one share, reducing the total outstanding shares to approximately 592,373.
  • The new CUSIP number for the common stock is 09076W406, while the CUSIP for publicly traded warrants remains unchanged.
  • Stockholders receiving fractional shares will be paid cash in lieu of such fractions.
  • The primary purpose of the reverse split is to comply with Nasdaq's minimum bid price requirement.
  • Proportionate adjustments will be made to stock options, stock incentive plans, & outstanding warrants regarding per-share exercise prices & share counts.
  • The transaction will occur automatically via transfer agent VStock Transfer LLC, which will send transaction notices to stockholders of record.
  • bioAffinity Technologies focuses on noninvasive early-stage cancer detection, with its first product being the CyPath® Lung Laboratory Developed Test.